Infectious Disease Point of Care Testing - US Analysis and Market Forecasts
With just under $700m in annual worldwide sales, the infectious disease point-of-care testing (POCT) market represents a major growth opportunity for in vitro diagnostics (IVD) companies looking to market products in this arena and address the need for faster, more accurate, and simpler diagnostic tests at the POC. The existing immunoassay-based infectious POC tests have not reached satisfactory performance levels to be comparable to lab-based tests for the adequate diagnosis of infections in low-prevalence settings. As such, physicians and lab technicians tend to perform lab tests to confirm the results they receive from current infectious POC tests. However, GlobalData expects that the entrance of true POC MDx platforms with integrated disposable devices within 5-10 years will become a major driver of growth for the adoption of POC infectious disease testing in developed markets. Nonetheless, in less established settings with high incidence of infectious diseases such as human immunodeficiency virus (HIV), tuberculosis (TB), and malaria, rapid infectious disease POCT tests developed according to the ASSURED criteria (affordable, sensitive, specific and user-friendly, rapid and robust, equipment-free, delivered) may provide a means for sufficiently controlling these diseases.
This report provides insight into the adoption trends, market dynamics, competitive landscape, marketed and pipeline products, current and emerging players, as well as market outlooks in the US. The report identifies the unmet needs in the market while providing an understanding of physicians’ perceptions in using and evaluating the adoption of different types of POC devices.
*This is an on-demand report and will be delivered within 4 working days (excluding weekends) of the purchase.
Key Questions Answered
- What is the current and future infectious disease POCT market outlook in the US? What trends are affecting the US market?
- What is the competitive landscape and market share of major players in the infectious disease POCT space in the US?
- What are the key, high growth markets that IVD manufacturers should expand into? Which market segments are growing the fastest?
- What are the unmet needs within infectious disease POCT? How will emerging technologies such as molecular POC assays fulfill these unmet needs?
- What are the key factors influencing a physician to use POC tests? What is physician perception and market outlook of infectious disease POC devices?
- What are the challenges and barriers that have hindered widespread adoption of infectious disease POCT?
Reasons to buy
- “What Do Physicians Think” quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Sales for the Infectious Disease POCT Market
2.2 Market Dynamics
2.3 Key Players in the Infectious Disease POCT Market
2.4 Infectious Disease POCT Market Future Outlook
2.5 What Do Physicians Think?
3.2 Related Reports
4 Industry Overview
4.1 Infectious Disease POCT Overview
4.2 Reimbursement Trends
4.3 Mergers, Acquisitions, and Key Partnerships
5 Unmet Needs
5.2 Sensitivity of Infectious Disease Immunoassays
5.3 Analytical Performance
5.4 Data Recording and Management
5.5 Infectious Disease POCT to Curb Usage of Antibiotics
5.6 Cost-Effectiveness Data
5.7 Primary Care Physician Needs
6 Competitive Assessment
6.1 Company Share Analysis
6.2.2 Marketed Products Assessment
6.2.3 SWOT Analysis
6.3 Beckman Coulter
6.3.2 Marketed Products Assessment
6.3.3 SWOT Analysis
6.4.2 Marketed Products Assessment
6.4.3 SWOT Analysis
6.5.2 Marketed Products Assessment
6.5.3 SWOT Analysis
6.6 Chembio Diagnostics
6.6.2 Marketed Products Assessment
6.6.3 SWOT Analysis
6.7 Meridian Bioscience
6.7.2 Marketed Products Assessment
6.7.3 SWOT Analysis
6.8 OraSure Technologies
6.8.2 Marketed Products Assessment
6.8.3 SWOT Analysis
6.9.2 Marketed Products Assessment
6.9.3 SWOT Analysis
6.10 Roche Diagnostics
6.10.2 Marketed Products Assessment
6.10.3 SWOT Analysis
6.11 Trinity Biotech
6.11.2 Marketed Products Assessment
6.11.3 SWOT Analysis
6.12 Other Companies
6.12.1 North American Market Companies
6.12.2 European Market Companies
6.12.3 APAC and Other Markets Companies
7 Pipeline Assessment
7.2 Early Development Pipelines
7.3 Pre-Clinical Stage Pipelines
7.4 Clinical Stage Pipelines
7.5 Pipelines in Approval Process
8 Market Outlook
8.1 Test Trends
8.1.1 HIV POCT
8.1.2 Influenza POCT
8.1.3 HBV POCT
8.1.4 HCV POCT
8.1.5 C. difficile POCT
8.2 Market Dynamics
8.2.1 Driver: Fast Turnaround Time
8.2.2 Driver: Emergence of Molecular Infectious Disease POCT
8.2.3 Driver: Expansion POCT Menu
8.2.4 Driver: CLIA-waived Status for POCT
8.2.5 Driver: Rising Prevalence of Diseases
8.2.6 Barriers: Management of POCT
8.2.7 Barriers: Competition with Laboratory Tests
8.2.8 Barriers: Reimbursement
8.2.9 Barriers: Regulatory Compliance
8.3 Market Outlook By Market Segment
8.3.2 HIV POCT
8.3.3 Influenza POCT
8.3.4 HBV POCT
8.3.5 HCV POCT
8.3.6 C. Difficile POCT
8.3.7 Molecular POCT Analyzers
8.4 Market Outlook By Geography
9.3 Report Methodology
9.3.3 Secondary Research
9.3.4 Forecasting Methodology
9.3.5 Primary Research - Key Opinion Leader Interviews
9.3.6 Primary Research - Physician and Industry Interviews
9.3.7 Expert Panel Validation
9.4 About the Team
9.4.2 Tyler Fletcher, Global Head of Medical Devices
9.5 About MediPoint
9.6 About GlobalData
9.7 Contact Us
1.2 List of Figures
Figure 1: Infectious Disease POCT Market Revenue, by Major Market , 2015 and 2022
Figure 2: Global Infectious Disease POCT Market, By Company Share, 2015
Figure 3: Infectious Disease POCT Pipelines, by Stage of Development, 2016
Figure 4: Global HIV POCT Volume Forecast (thousands) by Region, 2013-2022
Figure 5: Global Influenza POCT Volume Forecast (thousands) by Region, 2013-2022
Figure 6: Global HBV POCT Volume Forecast (thousands) by Region, 2013-2022
Figure 7: Global HCV POCT Volume Forecast (thousands) by Region, 2013-2022
Figure 8: Global C. difficile POCT Volume Forecast (thousands) by Region, 2013-2022
Figure 9: Global Infectious Disease POCT Sales Forecast ($m) by Market Segment, 2013-2022
Figure 10: : Global Infectious Disease POCT Market Share Forecast ($m) by Segment, 2015 and 2022
Figure 11: HIV POCT Sales Forecast ($m), 2013-2022
Figure 12: Influenza POCT Sales Forecast ($m), 2013-2022
Figure 13: HBV POCT Sales Forecast ($m), 2013-2022
Figure 14: HCV POCT Sales Forecast ($m), 2013-2022
Figure 15: C. difficile POCT Sales Forecast ($m), 2013-2022
Figure 16: Molecular POCT Analyzers Sales Forecast ($m), 2013-2022
Figure 17: US Infectious Disease POCT Sales Forecast ($m), 2013-2022
Figure 18: US Infectious Disease POCT Market Share Forecast (%) by Segment, 2015 and 2022
Figure 19: Infectious Disease POCT - Physician Survey Count by Country (N=121)
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.